FIELD: medicine, pharmaceutics.
SUBSTANCE: invention belongs to pharmaceutics and refers to tablet which contains as active component pharmaceutically acceptable salt of compound with formula in alpha crystallin form; active component's quantity is 30-80% of tablet mass.
EFFECT: manufacture of tablet with high concentration drug.
14 cl, 3 ex, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
TABLET WITH HIGH DRUG CONTENT | 2003 |
|
RU2363450C2 |
DISPERSED TABLETS DEFERASIROKS | 2003 |
|
RU2338532C2 |
NEW COMPOSITION | 2006 |
|
RU2821230C2 |
NOVEL COMPOSITION | 2006 |
|
RU2483716C2 |
HALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2005 |
|
RU2384328C2 |
PHARMACEUTICAL COMPOSITIONS, CONTAINING IMATINIB AND RELEASE MODERATOR | 2006 |
|
RU2404775C2 |
GALENIC COMPOSITIONS OF ORGANIC COMPOUNDS | 2009 |
|
RU2438661C2 |
SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING COMBINATION OF VILDAGLIPTIN AND GLIQUIDONE | 2014 |
|
RU2585378C1 |
ORAL SOLID DOSAGE FORM AND METHOD OF TREATING | 2011 |
|
RU2480210C1 |
MATRIX TABLET WITH MODIFIED NERAMEXANE RELEASE | 2006 |
|
RU2422135C2 |
Authors
Dates
2010-12-10—Published
2009-04-08—Filed